OncoTargets and Therapy (Nov 2019)
Temozolomide Combined With Capecitabine In The Treatment Of Mixed Neuroendocrine Carcinoma Of The Lung With Poor Tolerance After Repeated Radiochemotherapy: A Case Report And Literature Review
Abstract
Bin Zhang,1,2,* Di Wang,1,* Xia Zhang,3 Xiaonan Cui,1 Li Kong,1 Minghuan Li,2 Jinming Yu2 1Department of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian, People’s Republic of China; 2Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, People’s Republic of China; 3Department of Oncology, The Fifth People’s Hospital of Dalian, Dalian, People’s Republic of China*These authors contributed equally to this workCorrespondence: Minghuan Li; Jinming YuShandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, No. 440, Yanzhou Road, Jinan 250117, People’s Republic of ChinaTel +86531-87984777Fax +0531-87984079Email [email protected]; [email protected]: The incidence of lung neuroendocrine carcinomas, which originate from lung neuroendocrine cells, is 1.35/100,000, among which mixed neuroendocrine carcinomas are very rare. Because of the heterogeneity and significant differences in sensitivity to treatments, there is no effective treatment, and the prognosis is poor. In this article, we report the diagnosis and treatment of a case of mixed neuroendocrine carcinoma of the lung in our hospital. During the treatment, the patients had significant myelosuppression after initial chemotherapy, but benefited from oral chemotherapy consisting of a combination of capecitabine and temozolomide (CAPTEM). The report was approved by the affiliated Cancer Hospital of Shandong University.Keywords: temozolomide, mixed neuroendocrine carcinoma, case report, poor tolerance, lung cancer, review
